Troriluzole information

Troriluzole
Clinical data
Other names	Trigriluzole, BHV-4157, FC-4157
Routes of; administration	By mouth
Identifiers
	IUPAC name 2-amino-N-[2-[methyl-[2-oxo-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]ethyl]amino]-2-oxoethyl]acetamide;
CAS Number	1926203-09-9;
PubChem CID	121488186;
DrugBank	DB15079;
ChemSpider	58828005;
UNII	S7H48S6K7H;
KEGG	D11414;
ChEMBL	ChEMBL4297586;
Chemical and physical data
Formula	C15H16F3N5O4S
Molar mass	419.38 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN;
	InChI InChI=1S/C15H16F3N5O4S/c1-23(13(26)6-20-11(24)5-19)7-12(25)22-14-21-9-3-2-8(4-10(9)28-14)27-15(16,17)18/h2-4H,5-7,19H2,1H3,(H,20,24)(H,21,22,25); Key:YBZSGIWIPOUSHY-UHFFFAOYSA-N;

Troriluzole (trigriluzole) is an experimental medication that has been investigated as a potential treatment for spinocerebellar ataxia type 3 (SCA3),^[1]^[2]^[3]^[4] obsessive-compulsive disorder,^[3]^[4] and glioblastoma.^[5] It is a prodrug formulation of the medication riluzole.^[3]^[5]

^ Meglio, Marco (25 June 2023). "Biohaven Submits New Drug Application for Troriluzole as Spinocerebellar Ataxia Type 3 Therapy". NeurologyLive. Retrieved 17 February 2024.
^ Waldron, James (27 July 2023). "Further blow for Biohaven as FDA refuses to consider failed rare disease drug for approval". Fierce Biotech. Retrieved 17 February 2024.
^ ^a ^b ^c Grassi G, Cecchelli C, Vignozzi L, Pacini S (2020). "Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder". Journal of Experimental Pharmacology. 12: 695–706. doi:10.2147/JEP.S255375. PMC 7801912. PMID 33447096.
^ ^a ^b van Roessel PJ, Grassi G, Aboujaoude EN, Menchón JM, Van Ameringen M, Rodríguez CI (January 2023). "Treatment-resistant OCD: Pharmacotherapies in adults". Comprehensive Psychiatry. 120: 152352. doi:10.1016/j.comppsych.2022.152352. hdl:2445/192315. PMID 36368186.
^ ^a ^b Silk AW, Saraiya B, Groisberg R, Chan N, Spencer K, Girda E, Shih W, Palmeri M, Saunders T, Berman RM, Coric V, Chen S, Zloza A, Vieth J, Mehnert JM, Malhotra J (July 2022). "A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors". European Journal of Medical Research. 27 (1): 107. doi:10.1186/s40001-022-00732-w. PMC 9250196. PMID 35780243.

[Meglio_2023-1] Meglio, Marco (25 June 2023). "Biohaven Submits New Drug Application for Troriluzole as Spinocerebellar Ataxia Type 3 Therapy". NeurologyLive. Retrieved 17 February 2024.

[Waldron_2023-2] Waldron, James (27 July 2023). "Further blow for Biohaven as FDA refuses to consider failed rare disease drug for approval". Fierce Biotech. Retrieved 17 February 2024.

[pmid33447096-3] Grassi G, Cecchelli C, Vignozzi L, Pacini S (2020). "Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder". Journal of Experimental Pharmacology. 12: 695–706. doi:10.2147/JEP.S255375. PMC 7801912. PMID 33447096.

[pmid36368186-4] van Roessel PJ, Grassi G, Aboujaoude EN, Menchón JM, Van Ameringen M, Rodríguez CI (January 2023). "Treatment-resistant OCD: Pharmacotherapies in adults". Comprehensive Psychiatry. 120: 152352. doi:10.1016/j.comppsych.2022.152352. hdl:2445/192315. PMID 36368186.

[pmid35780243-5] Silk AW, Saraiya B, Groisberg R, Chan N, Spencer K, Girda E, Shih W, Palmeri M, Saunders T, Berman RM, Coric V, Chen S, Zloza A, Vieth J, Mehnert JM, Malhotra J (July 2022). "A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors". European Journal of Medical Research. 27 (1): 107. doi:10.1186/s40001-022-00732-w. PMC 9250196. PMID 35780243.

Troriluzole information

and 3 Related for: Troriluzole information

Troriluzole

Riluzole

ATC code N07

Clinical data

Other names	Trigriluzole, BHV-4157, FC-4157
Routes of administration	By mouth
Identifiers
IUPAC name 2-amino-N-[2-[methyl-[2-oxo-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]ethyl]amino]-2-oxoethyl]acetamide
CAS Number	1926203-09-9
PubChem CID	121488186
DrugBank	DB15079
ChemSpider	58828005
UNII	S7H48S6K7H
KEGG	D11414
ChEMBL	ChEMBL4297586
Chemical and physical data
Formula	C₁₅H₁₆F₃N₅O₄S
Molar mass	419.38 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN
InChI InChI=1S/C15H16F3N5O4S/c1-23(13(26)6-20-11(24)5-19)7-12(25)22-14-21-9-3-2-8(4-10(9)28-14)27-15(16,17)18/h2-4H,5-7,19H2,1H3,(H,20,24)(H,21,22,25) Key:YBZSGIWIPOUSHY-UHFFFAOYSA-N